Cough Suppressant Drugs Market Size & Share

Upcoming

2023

Cough Suppressant Drugs Market

by Indication (Dry Cough, Wet Cough), by Drug Type (Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, Pholcodine, Others), by Dosage Form (Syrup, Tablet, Others) and by Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals	Report Code: A13347	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cough Suppressant Drugs Market

Request Now !

Cough is a sudden expulsion of air through breathing passage that helps to clear mucous or fluids, foreign particles, and microbes. It is a protective reflex action and can be repetitive. Frequent coughing indicates presence of any irritation or disease. Choking, smoking, air pollution, asthama, bacterial infection, chronic bronchitis, lung tumors, and others can be the causes of cough. Cough can be divided into acute cough and chronic cough. Cough suppressants inhibit coughing and irritation in throat. Dextromethorphan, salbutamol, inhaled corticosteroids, and benzonatate are the some drugs which can be used as cough suppressants.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the cough suppressant drugs market.

Top Impacting Factors

Increase in prevalence of cough all over the globe, surge in adoption of unhealthy lifestyle, rise in consumption of cigarettes, increase in cases of respiratory tract infection, rise in high risk due to exposure to pollens, and surge in geriatric population are the key factors that drive the growth of the market.
In addition, surge in adoption of highly advance cough suppressant drugs, emerging advance technology in developing countries, R&D activities to improve quality of drugs, launch of novel drugs, rise in infrastructure developments through government funding, and aggressive development strategies by key market players are expected to boost the growth of the market.
However, side effects related to cough suppressant drugs and stringent regulation for over the counter medicines hinder the growth of the market.
Contrarily, increase in demand of cost effective treatment and government support for fast track regulatory approvals are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2021, Ernest Chemists announced launch of new herbal cough remedy named as Honeykof. This product use in treatment of throat infection and reduce amount of cough.

In 2018, Perrigo Company Plc, announced FDA approval for launch of its OTC brand Mucinex DM Maximum Strength. This product use to reduce repetitive cough and break up mucus.

Key Benefits of the Report

This study presents the analytical depiction of cough suppressant drugs market industry along with the current trends and future estimations to determine the imminent investment pockets.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
The current market is quantitatively analyzed to highlight the market growth scenario.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Cough Suppressant Drugs Market Report

Which are the leading players active in the cough suppressant drugs market?
What are the current trends that will influence the market in the next few years?
What are the driving factors, restraints, and opportunities of the market?
What future projections would help in taking further strategic steps?
What is "cough suppressant drugs"?
What is "cough suppressant drugs" market prediction in the future?
Who are the leading global players in the "cough suppressant" market?
What are the current trends and predicted trends?
What are the key benefits of the "cough suppressant drugs" market report?

Cough Suppressant Drugs Market Report Highlights

Aspects	Details
By Indication	Dry Cough Wet Cough
By Drug Type	Dextromethorphan Codeine Noscapine Butamirate Benzonatate Pholcodine Others
By Dosage Form	Syrup Tablet Others
By Distribution Channel	Hospitals Pharmacy Retail Pharmacy Online Pharmacy
By Region	North America Europe Asia-Pacific LAMEA
Key Market Players	Acella Pharmaceuticals LLC, Taro Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd, GlaxoSmithKline plc., Vernalis plc,, Perrigo Company plc, Aytu BioScience, Inc., Pfizer Inc., Mayne Pharma Inc., Amneal Pharmaceuticals LLC

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: COUGH SUPPRESSANT DRUGS MARKET, BY INDICATION
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Indication
- 4.2. Dry Cough
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
- 4.3. Wet Cough
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
CHAPTER 5: COUGH SUPPRESSANT DRUGS MARKET, BY DRUG TYPE
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Drug Type
- 5.2. Dextromethorphan
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Codeine
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
- 5.4. Noscapine
  - 5.4.1. Key Market Trends, Growth Factors and Opportunities
  - 5.4.2. Market Size and Forecast, By Region
  - 5.4.3. Market Share Analysis, By Country
- 5.5. Butamirate
  - 5.5.1. Key Market Trends, Growth Factors and Opportunities
  - 5.5.2. Market Size and Forecast, By Region
  - 5.5.3. Market Share Analysis, By Country
- 5.6. Benzonatate
  - 5.6.1. Key Market Trends, Growth Factors and Opportunities
  - 5.6.2. Market Size and Forecast, By Region
  - 5.6.3. Market Share Analysis, By Country
- 5.7. Pholcodine
  - 5.7.1. Key Market Trends, Growth Factors and Opportunities
  - 5.7.2. Market Size and Forecast, By Region
  - 5.7.3. Market Share Analysis, By Country
- 5.8. Others
  - 5.8.1. Key Market Trends, Growth Factors and Opportunities
  - 5.8.2. Market Size and Forecast, By Region
  - 5.8.3. Market Share Analysis, By Country
CHAPTER 6: COUGH SUPPRESSANT DRUGS MARKET, BY DOSAGE FORM
- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By Dosage Form
- 6.2. Syrup
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Tablet
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region
  - 6.3.3. Market Share Analysis, By Country
- 6.4. Others
  - 6.4.1. Key Market Trends, Growth Factors and Opportunities
  - 6.4.2. Market Size and Forecast, By Region
  - 6.4.3. Market Share Analysis, By Country
CHAPTER 7: COUGH SUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By Distribution Channel
- 7.2. Hospitals Pharmacy
  - 7.2.1. Key Market Trends, Growth Factors and Opportunities
  - 7.2.2. Market Size and Forecast, By Region
  - 7.2.3. Market Share Analysis, By Country
- 7.3. Retail Pharmacy
  - 7.3.1. Key Market Trends, Growth Factors and Opportunities
  - 7.3.2. Market Size and Forecast, By Region
  - 7.3.3. Market Share Analysis, By Country
- 7.4. Online Pharmacy
  - 7.4.1. Key Market Trends, Growth Factors and Opportunities
  - 7.4.2. Market Size and Forecast, By Region
  - 7.4.3. Market Share Analysis, By Country
CHAPTER 8: COUGH SUPPRESSANT DRUGS MARKET, BY REGION
- 8.1. Market Overview
  - 8.1.1 Market Size and Forecast, By Region
- 8.2. North America
  - 8.2.1. Key Market Trends and Opportunities
  - 8.2.2. Market Size and Forecast, By Indication
  - 8.2.3. Market Size and Forecast, By Drug Type
  - 8.2.4. Market Size and Forecast, By Dosage Form
  - 8.2.5. Market Size and Forecast, By Distribution Channel
  - 8.2.6. Market Size and Forecast, By Country
  - 8.2.7. U.S. Cough Suppressant Drugs Market
    - 8.2.7.1. Market Size and Forecast, By Indication
    - 8.2.7.2. Market Size and Forecast, By Drug Type
    - 8.2.7.3. Market Size and Forecast, By Dosage Form
    - 8.2.7.4. Market Size and Forecast, By Distribution Channel
  - 8.2.8. Canada Cough Suppressant Drugs Market
    - 8.2.8.1. Market Size and Forecast, By Indication
    - 8.2.8.2. Market Size and Forecast, By Drug Type
    - 8.2.8.3. Market Size and Forecast, By Dosage Form
    - 8.2.8.4. Market Size and Forecast, By Distribution Channel
  - 8.2.9. Mexico Cough Suppressant Drugs Market
    - 8.2.9.1. Market Size and Forecast, By Indication
    - 8.2.9.2. Market Size and Forecast, By Drug Type
    - 8.2.9.3. Market Size and Forecast, By Dosage Form
    - 8.2.9.4. Market Size and Forecast, By Distribution Channel
- 8.3. Europe
  - 8.3.1. Key Market Trends and Opportunities
  - 8.3.2. Market Size and Forecast, By Indication
  - 8.3.3. Market Size and Forecast, By Drug Type
  - 8.3.4. Market Size and Forecast, By Dosage Form
  - 8.3.5. Market Size and Forecast, By Distribution Channel
  - 8.3.6. Market Size and Forecast, By Country
  - 8.3.7. France Cough Suppressant Drugs Market
    - 8.3.7.1. Market Size and Forecast, By Indication
    - 8.3.7.2. Market Size and Forecast, By Drug Type
    - 8.3.7.3. Market Size and Forecast, By Dosage Form
    - 8.3.7.4. Market Size and Forecast, By Distribution Channel
  - 8.3.8. Germany Cough Suppressant Drugs Market
    - 8.3.8.1. Market Size and Forecast, By Indication
    - 8.3.8.2. Market Size and Forecast, By Drug Type
    - 8.3.8.3. Market Size and Forecast, By Dosage Form
    - 8.3.8.4. Market Size and Forecast, By Distribution Channel
  - 8.3.9. Italy Cough Suppressant Drugs Market
    - 8.3.9.1. Market Size and Forecast, By Indication
    - 8.3.9.2. Market Size and Forecast, By Drug Type
    - 8.3.9.3. Market Size and Forecast, By Dosage Form
    - 8.3.9.4. Market Size and Forecast, By Distribution Channel
  - 8.3.10. Spain Cough Suppressant Drugs Market
    - 8.3.10.1. Market Size and Forecast, By Indication
    - 8.3.10.2. Market Size and Forecast, By Drug Type
    - 8.3.10.3. Market Size and Forecast, By Dosage Form
    - 8.3.10.4. Market Size and Forecast, By Distribution Channel
  - 8.3.11. UK Cough Suppressant Drugs Market
    - 8.3.11.1. Market Size and Forecast, By Indication
    - 8.3.11.2. Market Size and Forecast, By Drug Type
    - 8.3.11.3. Market Size and Forecast, By Dosage Form
    - 8.3.11.4. Market Size and Forecast, By Distribution Channel
  - 8.3.12. Russia Cough Suppressant Drugs Market
    - 8.3.12.1. Market Size and Forecast, By Indication
    - 8.3.12.2. Market Size and Forecast, By Drug Type
    - 8.3.12.3. Market Size and Forecast, By Dosage Form
    - 8.3.12.4. Market Size and Forecast, By Distribution Channel
  - 8.3.13. Rest Of Europe Cough Suppressant Drugs Market
    - 8.3.13.1. Market Size and Forecast, By Indication
    - 8.3.13.2. Market Size and Forecast, By Drug Type
    - 8.3.13.3. Market Size and Forecast, By Dosage Form
    - 8.3.13.4. Market Size and Forecast, By Distribution Channel
- 8.4. Asia-Pacific
  - 8.4.1. Key Market Trends and Opportunities
  - 8.4.2. Market Size and Forecast, By Indication
  - 8.4.3. Market Size and Forecast, By Drug Type
  - 8.4.4. Market Size and Forecast, By Dosage Form
  - 8.4.5. Market Size and Forecast, By Distribution Channel
  - 8.4.6. Market Size and Forecast, By Country
  - 8.4.7. China Cough Suppressant Drugs Market
    - 8.4.7.1. Market Size and Forecast, By Indication
    - 8.4.7.2. Market Size and Forecast, By Drug Type
    - 8.4.7.3. Market Size and Forecast, By Dosage Form
    - 8.4.7.4. Market Size and Forecast, By Distribution Channel
  - 8.4.8. Japan Cough Suppressant Drugs Market
    - 8.4.8.1. Market Size and Forecast, By Indication
    - 8.4.8.2. Market Size and Forecast, By Drug Type
    - 8.4.8.3. Market Size and Forecast, By Dosage Form
    - 8.4.8.4. Market Size and Forecast, By Distribution Channel
  - 8.4.9. India Cough Suppressant Drugs Market
    - 8.4.9.1. Market Size and Forecast, By Indication
    - 8.4.9.2. Market Size and Forecast, By Drug Type
    - 8.4.9.3. Market Size and Forecast, By Dosage Form
    - 8.4.9.4. Market Size and Forecast, By Distribution Channel
  - 8.4.10. South Korea Cough Suppressant Drugs Market
    - 8.4.10.1. Market Size and Forecast, By Indication
    - 8.4.10.2. Market Size and Forecast, By Drug Type
    - 8.4.10.3. Market Size and Forecast, By Dosage Form
    - 8.4.10.4. Market Size and Forecast, By Distribution Channel
  - 8.4.11. Australia Cough Suppressant Drugs Market
    - 8.4.11.1. Market Size and Forecast, By Indication
    - 8.4.11.2. Market Size and Forecast, By Drug Type
    - 8.4.11.3. Market Size and Forecast, By Dosage Form
    - 8.4.11.4. Market Size and Forecast, By Distribution Channel
  - 8.4.12. Thailand Cough Suppressant Drugs Market
    - 8.4.12.1. Market Size and Forecast, By Indication
    - 8.4.12.2. Market Size and Forecast, By Drug Type
    - 8.4.12.3. Market Size and Forecast, By Dosage Form
    - 8.4.12.4. Market Size and Forecast, By Distribution Channel
  - 8.4.13. Malaysia Cough Suppressant Drugs Market
    - 8.4.13.1. Market Size and Forecast, By Indication
    - 8.4.13.2. Market Size and Forecast, By Drug Type
    - 8.4.13.3. Market Size and Forecast, By Dosage Form
    - 8.4.13.4. Market Size and Forecast, By Distribution Channel
  - 8.4.14. Indonesia Cough Suppressant Drugs Market
    - 8.4.14.1. Market Size and Forecast, By Indication
    - 8.4.14.2. Market Size and Forecast, By Drug Type
    - 8.4.14.3. Market Size and Forecast, By Dosage Form
    - 8.4.14.4. Market Size and Forecast, By Distribution Channel
  - 8.4.15. Rest of Asia Pacific Cough Suppressant Drugs Market
    - 8.4.15.1. Market Size and Forecast, By Indication
    - 8.4.15.2. Market Size and Forecast, By Drug Type
    - 8.4.15.3. Market Size and Forecast, By Dosage Form
    - 8.4.15.4. Market Size and Forecast, By Distribution Channel
- 8.5. LAMEA
  - 8.5.1. Key Market Trends and Opportunities
  - 8.5.2. Market Size and Forecast, By Indication
  - 8.5.3. Market Size and Forecast, By Drug Type
  - 8.5.4. Market Size and Forecast, By Dosage Form
  - 8.5.5. Market Size and Forecast, By Distribution Channel
  - 8.5.6. Market Size and Forecast, By Country
  - 8.5.7. Brazil Cough Suppressant Drugs Market
    - 8.5.7.1. Market Size and Forecast, By Indication
    - 8.5.7.2. Market Size and Forecast, By Drug Type
    - 8.5.7.3. Market Size and Forecast, By Dosage Form
    - 8.5.7.4. Market Size and Forecast, By Distribution Channel
  - 8.5.8. South Africa Cough Suppressant Drugs Market
    - 8.5.8.1. Market Size and Forecast, By Indication
    - 8.5.8.2. Market Size and Forecast, By Drug Type
    - 8.5.8.3. Market Size and Forecast, By Dosage Form
    - 8.5.8.4. Market Size and Forecast, By Distribution Channel
  - 8.5.9. Saudi Arabia Cough Suppressant Drugs Market
    - 8.5.9.1. Market Size and Forecast, By Indication
    - 8.5.9.2. Market Size and Forecast, By Drug Type
    - 8.5.9.3. Market Size and Forecast, By Dosage Form
    - 8.5.9.4. Market Size and Forecast, By Distribution Channel
  - 8.5.10. UAE Cough Suppressant Drugs Market
    - 8.5.10.1. Market Size and Forecast, By Indication
    - 8.5.10.2. Market Size and Forecast, By Drug Type
    - 8.5.10.3. Market Size and Forecast, By Dosage Form
    - 8.5.10.4. Market Size and Forecast, By Distribution Channel
  - 8.5.11. Argentina Cough Suppressant Drugs Market
    - 8.5.11.1. Market Size and Forecast, By Indication
    - 8.5.11.2. Market Size and Forecast, By Drug Type
    - 8.5.11.3. Market Size and Forecast, By Dosage Form
    - 8.5.11.4. Market Size and Forecast, By Distribution Channel
  - 8.5.12. Rest of LAMEA Cough Suppressant Drugs Market
    - 8.5.12.1. Market Size and Forecast, By Indication
    - 8.5.12.2. Market Size and Forecast, By Drug Type
    - 8.5.12.3. Market Size and Forecast, By Dosage Form
    - 8.5.12.4. Market Size and Forecast, By Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping Of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning,2022
CHAPTER 10: COMPANY PROFILES
- 10.1. Pfizer Inc.
  - 10.1.1. Company Overview
  - 10.1.2. Key Executives
  - 10.1.3. Company Snapshot
  - 10.1.4. Operating Business Segments
  - 10.1.5. Product Portfolio
  - 10.1.6. Business Performance
  - 10.1.7. Key Strategic Moves and Developments
- 10.2. Aytu BioScience, Inc.
  - 10.2.1. Company Overview
  - 10.2.2. Key Executives
  - 10.2.3. Company Snapshot
  - 10.2.4. Operating Business Segments
  - 10.2.5. Product Portfolio
  - 10.2.6. Business Performance
  - 10.2.7. Key Strategic Moves and Developments
- 10.3. Acella Pharmaceuticals LLC
  - 10.3.1. Company Overview
  - 10.3.2. Key Executives
  - 10.3.3. Company Snapshot
  - 10.3.4. Operating Business Segments
  - 10.3.5. Product Portfolio
  - 10.3.6. Business Performance
  - 10.3.7. Key Strategic Moves and Developments
- 10.4. Mayne Pharma Inc.
  - 10.4.1. Company Overview
  - 10.4.2. Key Executives
  - 10.4.3. Company Snapshot
  - 10.4.4. Operating Business Segments
  - 10.4.5. Product Portfolio
  - 10.4.6. Business Performance
  - 10.4.7. Key Strategic Moves and Developments
- 10.5. Taro Pharmaceutical Industries Ltd.
  - 10.5.1. Company Overview
  - 10.5.2. Key Executives
  - 10.5.3. Company Snapshot
  - 10.5.4. Operating Business Segments
  - 10.5.5. Product Portfolio
  - 10.5.6. Business Performance
  - 10.5.7. Key Strategic Moves and Developments
- 10.6. Amneal Pharmaceuticals LLC
  - 10.6.1. Company Overview
  - 10.6.2. Key Executives
  - 10.6.3. Company Snapshot
  - 10.6.4. Operating Business Segments
  - 10.6.5. Product Portfolio
  - 10.6.6. Business Performance
  - 10.6.7. Key Strategic Moves and Developments
- 10.7. Aurobindo Pharma Ltd
  - 10.7.1. Company Overview
  - 10.7.2. Key Executives
  - 10.7.3. Company Snapshot
  - 10.7.4. Operating Business Segments
  - 10.7.5. Product Portfolio
  - 10.7.6. Business Performance
  - 10.7.7. Key Strategic Moves and Developments
- 10.8. GlaxoSmithKline Plc.
  - 10.8.1. Company Overview
  - 10.8.2. Key Executives
  - 10.8.3. Company Snapshot
  - 10.8.4. Operating Business Segments
  - 10.8.5. Product Portfolio
  - 10.8.6. Business Performance
  - 10.8.7. Key Strategic Moves and Developments
- 10.9. Perrigo Company Plc
  - 10.9.1. Company Overview
  - 10.9.2. Key Executives
  - 10.9.3. Company Snapshot
  - 10.9.4. Operating Business Segments
  - 10.9.5. Product Portfolio
  - 10.9.6. Business Performance
  - 10.9.7. Key Strategic Moves and Developments
- 10.10. Vernalis Plc,
  - 10.10.1. Company Overview
  - 10.10.2. Key Executives
  - 10.10.3. Company Snapshot
  - 10.10.4. Operating Business Segments
  - 10.10.5. Product Portfolio
  - 10.10.6. Business Performance
  - 10.10.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 2. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR DRY COUGH, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR WET COUGH, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 5. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR DEXTROMETHORPHAN, BY REGION, 2022-2032 ($MILLION)
TABLE 6. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR CODEINE, BY REGION, 2022-2032 ($MILLION)
TABLE 7. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR NOSCAPINE, BY REGION, 2022-2032 ($MILLION)
TABLE 8. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR BUTAMIRATE, BY REGION, 2022-2032 ($MILLION)
TABLE 9. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR BENZONATATE, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR PHOLCODINE, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 13. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR SYRUP, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR TABLET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 16. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR HOSPITALS PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 18. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 19. GLOBAL COUGH SUPPRESSANT DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 20. GLOBAL COUGH SUPPRESSANT DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. U.S. COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 27. U.S. COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 28. U.S. COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 29. U.S. COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. CANADA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 31. CANADA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 32. CANADA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 33. CANADA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. MEXICO COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 35. MEXICO COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 36. MEXICO COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 37. MEXICO COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. EUROPE COUGH SUPPRESSANT DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 39. EUROPE COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 40. EUROPE COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 41. EUROPE COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 42. EUROPE COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. FRANCE COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 44. FRANCE COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 45. FRANCE COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 46. FRANCE COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. GERMANY COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 48. GERMANY COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 49. GERMANY COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 50. GERMANY COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ITALY COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 52. ITALY COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 53. ITALY COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 54. ITALY COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. SPAIN COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 56. SPAIN COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. SPAIN COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 58. SPAIN COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. UK COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 60. UK COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 61. UK COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 62. UK COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. RUSSIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 64. RUSSIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 65. RUSSIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 66. RUSSIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. REST OF EUROPE COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 68. REST OF EUROPE COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF EUROPE COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 70. REST OF EUROPE COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 72. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 73. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 74. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 75. ASIA-PACIFIC COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. CHINA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 77. CHINA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 78. CHINA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 79. CHINA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. JAPAN COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 81. JAPAN COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 82. JAPAN COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 83. JAPAN COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. INDIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 85. INDIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 86. INDIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 87. INDIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 90. SOUTH KOREA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 91. SOUTH KOREA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 92. AUSTRALIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 93. AUSTRALIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 94. AUSTRALIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 95. AUSTRALIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 96. THAILAND COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 97. THAILAND COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 98. THAILAND COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 99. THAILAND COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 100. MALAYSIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 101. MALAYSIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 102. MALAYSIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 103. MALAYSIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 104. INDONESIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 105. INDONESIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 106. INDONESIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 107. INDONESIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 108. REST OF ASIA PACIFIC COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 109. REST OF ASIA PACIFIC COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 110. REST OF ASIA PACIFIC COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 111. REST OF ASIA PACIFIC COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 112. LAMEA COUGH SUPPRESSANT DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 113. LAMEA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 114. LAMEA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 115. LAMEA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 116. LAMEA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 117. BRAZIL COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 118. BRAZIL COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 119. BRAZIL COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 120. BRAZIL COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 121. SOUTH AFRICA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 122. SOUTH AFRICA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 123. SOUTH AFRICA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 124. SOUTH AFRICA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 125. SAUDI ARABIA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 126. SAUDI ARABIA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 127. SAUDI ARABIA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 128. SAUDI ARABIA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 129. UAE COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 130. UAE COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 131. UAE COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 132. UAE COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 133. ARGENTINA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 134. ARGENTINA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 135. ARGENTINA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 136. ARGENTINA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 137. REST OF LAMEA COUGH SUPPRESSANT DRUGS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 138. REST OF LAMEA COUGH SUPPRESSANT DRUGS, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 139. REST OF LAMEA COUGH SUPPRESSANT DRUGS, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 140. REST OF LAMEA COUGH SUPPRESSANT DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 141. PFIZER INC.: KEY EXECUTIVES
TABLE 142. PFIZER INC.: COMPANY SNAPSHOT
TABLE 143. PFIZER INC.: OPERATING SEGMENTS
TABLE 144. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 145. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 146. AYTU BIOSCIENCE, INC.: KEY EXECUTIVES
TABLE 147. AYTU BIOSCIENCE, INC.: COMPANY SNAPSHOT
TABLE 148. AYTU BIOSCIENCE, INC.: OPERATING SEGMENTS
TABLE 149. AYTU BIOSCIENCE, INC.: PRODUCT PORTFOLIO
TABLE 150. AYTU BIOSCIENCE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 151. ACELLA PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 152. ACELLA PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 153. ACELLA PHARMACEUTICALS LLC: OPERATING SEGMENTS
TABLE 154. ACELLA PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 155. ACELLA PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 156. MAYNE PHARMA INC.: KEY EXECUTIVES
TABLE 157. MAYNE PHARMA INC.: COMPANY SNAPSHOT
TABLE 158. MAYNE PHARMA INC.: OPERATING SEGMENTS
TABLE 159. MAYNE PHARMA INC.: PRODUCT PORTFOLIO
TABLE 160. MAYNE PHARMA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 161. TARO PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 162. TARO PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 163. TARO PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 164. TARO PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 165. TARO PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 166. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 167. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 168. AMNEAL PHARMACEUTICALS LLC: OPERATING SEGMENTS
TABLE 169. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 170. AMNEAL PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 171. AUROBINDO PHARMA LTD: KEY EXECUTIVES
TABLE 172. AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
TABLE 173. AUROBINDO PHARMA LTD: OPERATING SEGMENTS
TABLE 174. AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
TABLE 175. AUROBINDO PHARMA LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 176. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
TABLE 177. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 178. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 179. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 180. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 181. PERRIGO COMPANY PLC: KEY EXECUTIVES
TABLE 182. PERRIGO COMPANY PLC: COMPANY SNAPSHOT
TABLE 183. PERRIGO COMPANY PLC: OPERATING SEGMENTS
TABLE 184. PERRIGO COMPANY PLC: PRODUCT PORTFOLIO
TABLE 185. PERRIGO COMPANY PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 186. VERNALIS PLC,: KEY EXECUTIVES
TABLE 187. VERNALIS PLC,: COMPANY SNAPSHOT
TABLE 188. VERNALIS PLC,: OPERATING SEGMENTS
TABLE 189. VERNALIS PLC,: PRODUCT PORTFOLIO
TABLE 190. VERNALIS PLC,: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION
FIGURE 2. GLOBAL COUGH SUPPRESSANT DRUGS MARKET
FIGURE 3. SEGMENTATION COUGH SUPPRESSANT DRUGS MARKET
FIGURE 4. TOP INVESTMENT POCKET IN COUGH SUPPRESSANT DRUGS MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCOUGH SUPPRESSANT DRUGS MARKET
FIGURE 11. COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY INDICATION
FIGURE 12. COUGH SUPPRESSANT DRUGS MARKET FOR DRY COUGH, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. COUGH SUPPRESSANT DRUGS MARKET FOR WET COUGH, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY DRUG TYPE
FIGURE 15. COUGH SUPPRESSANT DRUGS MARKET FOR DEXTROMETHORPHAN, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 16. COUGH SUPPRESSANT DRUGS MARKET FOR CODEINE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 17. COUGH SUPPRESSANT DRUGS MARKET FOR NOSCAPINE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 18. COUGH SUPPRESSANT DRUGS MARKET FOR BUTAMIRATE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 19. COUGH SUPPRESSANT DRUGS MARKET FOR BENZONATATE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 20. COUGH SUPPRESSANT DRUGS MARKET FOR PHOLCODINE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 21. COUGH SUPPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 22. COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY DOSAGE FORM
FIGURE 23. COUGH SUPPRESSANT DRUGS MARKET FOR SYRUP, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 24. COUGH SUPPRESSANT DRUGS MARKET FOR TABLET, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 25. COUGH SUPPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 26. COUGH SUPPRESSANT DRUGS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
FIGURE 27. COUGH SUPPRESSANT DRUGS MARKET FOR HOSPITALS PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 28. COUGH SUPPRESSANT DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 29. COUGH SUPPRESSANT DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 30. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 34. COMPETITIVE DASHBOARD
FIGURE 35. COMPETITIVE HEATMAP: COUGH SUPPRESSANT DRUGS MARKET
FIGURE 36. Top player positioning, 2022
FIGURE 37. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 38. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 39. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 40. AYTU BIOSCIENCE, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 41. AYTU BIOSCIENCE, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 42. AYTU BIOSCIENCE, INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 43. ACELLA PHARMACEUTICALS LLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 44. ACELLA PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 45. ACELLA PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 46. MAYNE PHARMA INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 47. MAYNE PHARMA INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 48. MAYNE PHARMA INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 49. TARO PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 50. TARO PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 51. TARO PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 52. AMNEAL PHARMACEUTICALS LLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 53. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 54. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 55. AUROBINDO PHARMA LTD: NET SALES, 2020-2022 ($MILLION)
FIGURE 56. AUROBINDO PHARMA LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 57. AUROBINDO PHARMA LTD: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 58. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 59. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 60. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 61. PERRIGO COMPANY PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 62. PERRIGO COMPANY PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 63. PERRIGO COMPANY PLC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 64. VERNALIS PLC,: NET SALES, 2020-2022 ($MILLION)
FIGURE 65. VERNALIS PLC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 66. VERNALIS PLC,: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Cough Suppressant Drugs Market Global Opportunity Analysis and Industry Forecast, 2023-2032

2023

Cough Suppressant Drugs Market

Cough Suppressant Drugs Market

COVID-19

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: COUGH SUPPRESSANT DRUGS MARKET, BY INDICATION

4.1. Market Overview

4.1.1 Market Size and Forecast, By Indication

4.2. Dry Cough

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Wet Cough

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

CHAPTER 5: COUGH SUPPRESSANT DRUGS MARKET, BY DRUG TYPE

5.1. Market Overview

5.1.1 Market Size and Forecast, By Drug Type

5.2. Dextromethorphan

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.2.2. Market Size and Forecast, By Region

5.2.3. Market Share Analysis, By Country

5.3. Codeine

5.3.1. Key Market Trends, Growth Factors and Opportunities

5.3.2. Market Size and Forecast, By Region

5.3.3. Market Share Analysis, By Country

5.4. Noscapine

5.4.1. Key Market Trends, Growth Factors and Opportunities

5.4.2. Market Size and Forecast, By Region

5.4.3. Market Share Analysis, By Country

5.5. Butamirate

5.5.1. Key Market Trends, Growth Factors and Opportunities

5.5.2. Market Size and Forecast, By Region

5.5.3. Market Share Analysis, By Country

5.6. Benzonatate

5.6.1. Key Market Trends, Growth Factors and Opportunities

5.6.2. Market Size and Forecast, By Region

5.6.3. Market Share Analysis, By Country

5.7. Pholcodine

5.7.1. Key Market Trends, Growth Factors and Opportunities

5.7.2. Market Size and Forecast, By Region

5.7.3. Market Share Analysis, By Country

5.8. Others

5.8.1. Key Market Trends, Growth Factors and Opportunities

5.8.2. Market Size and Forecast, By Region

5.8.3. Market Share Analysis, By Country

CHAPTER 6: COUGH SUPPRESSANT DRUGS MARKET, BY DOSAGE FORM

6.1. Market Overview

6.1.1 Market Size and Forecast, By Dosage Form

6.2. Syrup

6.2.1. Key Market Trends, Growth Factors and Opportunities

Cough Suppressant Drugs Market
Global Opportunity Analysis and Industry Forecast, 2023-2032